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To study the molecular immunologic features of allograft rejection and 
tolerance induction by intrathymic pretreatment we developed a murine 
model of cardiac transplantation. In this model the transplant recipient 
was the C57BL/6 mouse with its major histocompatibility phenotype H-2 b. 
Donors of cells for intrathymic pretreatment and of hearts for grafting were 
mice of the bml mutation. The bml mutation involves ubstitution of three 
amino acids in one of the alpha helixes of the class I H-2K b molecule. 
Because of the discrete molecular configuration of the transplant antigen 
we hypothesized that there would be limited heterogeneity of receptor 
expression on C57BL/6 T cells responding to bml cardiac grafts and that 
intrathymic pretreatment would alter the T-cell repertoire of graft recipi- 
ents by causing elimination of T cells responsible for graft rejection. Mice were 
given 0.3 ml of antilymphocyte s rum intraperitoneally and had intrathymic 
injection of 25 x 106 bml splenocytes 12 to 21 days before transplantation with 
a bml cardiac graft. Flow cytometric analysis of lymph node and spleen cells 
was used to study the V beta T-cell repertoire of graft recipients. Cells were 
stained with monoclonal antibodies to CD3 and 13 V beta regions (n = 5, each 
group) of T cells in naive, sensitized, and tolerant animals. Untreated C57BL/6 
mice (n = 9) rejected bml cardiac grafts a mean of 20.4 days after transplan- 
tation. Twelve mice pretreated with antilymphocyte s rum and intrathymic 
bml cells had permanent graft survival (>100 days, p < 0.0001). Animals 
treated with antilymphocyte s rum alone (n = 5) or pretreated animals 
undergoing third-party BALB/c grafts (n = 4) rejected grafts in the normal 
time frame. There was significant alteration of percentage r ceptor expression 
of V beta 5.1, 7, 12, 13, and 17a in sensitized and tolerant mice. Of interest, V
beta 7 expression was increased in the sensitized mice (3.8% to 8.3%,p = 0.005) 
and was virtually eliminated in tolerant mice (p = 0.005). In conclusion, these 
data suggest that V beta 7 is a critical receptor in the C57BL/6 response to 
subcutaneous bml cardiac grafts. Pretreatment of graft recipients with one 
dose of antilymphocyte s rum and intrathymic bml cells appears to produce 
permanent tolerance to bml grafts with elimination of T cells expressing 
receptor chain V beta 7. (J Thorac Cardiovasc Surg 1996;112:310-3) 
O rgan transplantation remains effective therapy for patients with end-stage organ dysfunction 
but results remain limited by the imperfections and 
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side effects of immunosuppressive therapy. Im- 
proved understanding of the rejection response and 
biologic methods to produce specific tolerance to 
grafted tissues will improve the results of organ 
transplantation. This is the age of molecular medi- 
cine. Understanding of the molecular immunologic 
basis of graft rejection and tissue-specific methods 
to prevent it will be required to produce fundamen- 
tal new advances in organ transplantation. 
We have developed an animal model of organ 
transplantation that allows studies of the processes 
of rejection and induction of tolerance at a molec- 
ular level. 1 We have used strains of mice as donor 
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(bml) and recipient of grafted tissue (C57BL/6) 
that differ only by substitution of three amino acids 
on one class I major histocompatibility complex 
(MHC) molecule. 2 The bin1 mutation contains a 
three-amino-acid substitution on one alpha helix of 
the H-2K b MHC molecule. This difference is suffi- 
cient to cause rejection of a subcutaneous cardiac 
graft an average of 20 days after transplantation. 
Our work and that of other laboratories have shown 
that intrathymic pretreatment of graft recipients 
with donor-specific ells produces allograft toler- 
ance in a rat model of cardiac transplantation. 3-aWe 
sought to reproduce and study this result in our 
murine model. 
Because the three-amino-acid difference between 
donor and recipient tissues produces a discrete 
molecular antigenic onfiguration, we hypothesized 
that a limited repertoire of T-cell receptors would 
be expressed on recipient C57BL/6 cells, causing 
rejection of bin1 grafts. If this were the case we 
reasoned that our model system would allow inves- 
tigation of the hypothesis that intrathymic pretreat- 
ment causes deletion of recipient T cells expressing 
this receptor chain. We believed that a deletion 
mechanism was plausible because this process ap- 
pears to be crucial in normal immune ontogeny. 
The present studies were designed to characterize 
the rejection response to subcutaneous cardiac 
grafts in our model system and to demonstrate 
induction of tolerance with the intrathymic pretreat- 
ment strateffy. Furthermore, we sought to examine 
the T-cell receptor repertoire on naive recipient 
mice, those rendered sensitized to donor tissue by 
rejection of a previous graft, and those rendered 
tolerant to donor tissue by intrathymic pretreat- 
ment. We believe that this model system and the 
results of our studies help us begin to develop a 
molecular understanding of these important events 
in organ transplantation. 
Material and methods 
Animals. Eight-week-old male C57BL/6 mice were 
used as the recipients of heart and intrathymic spleen 
cells. Male brnI mice of the same age were used as donors 
of heart and spleen cells. All animals were purchased from 
Jackson Laboratory and were housed in a virus-free 
facility. The C57BL/6 mouse is MHC phenotype H-2 b. 
The bin1 mutation differs only by substitution of three 
amino acids in one of the alpha helixes of the H-2K b 
molecule. 1 
All animals were cared for in compliance with the 
"Principles of Laboratory Animal Care" formulated by 
the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). 
Cardiac transplantation technique. We used the tech- 
nique of split ear cardiac grafting. 9 A pouch was made in 
the pinna of the C57BL/6 recipient mouse ar and a whole 
neonatal (24 to 48 hours old) heart from a bml donor was 
placed in it. This is not an immediately vascularized graft. 
Although operative time is short (<1 hour) graft contrac- 
tions uniformly do not start for 5 days. Graft survival as 
determined by the presence of ventricular pulsatile activ- 
ity was checked every day by visual inspection with a ×20 
dissecting microscope. Cessation of heartbeat after initial 
pulsatile activity was considered to be caused by rejection, 
which was confirmed histologically. All rejected grafts had 
infiltration by small ymphocytes and myocyte destruction 
seen on hematoxylin and eosin staining of tissue sections 
examined by light microscopy. Control isogenic grafts beat 
indefinitely once contractions start and are histologically 
normal on pathologic examination. 
Tolerance induction. Whole spleen was disrupted by 
passage through a wire mesh. Red blood cells were lysed 
with Tris NH4C1. Cells were washed with RPMI 1640 
medium and were injected intrathymically under direct 
vision at a concentration f 25 × 106 cells in 0.5 ml of the 
medium. Cells were injected 1 day after intraperitoneal 
injection of 0.3 ml murine antilymphocyte s rum (ALS) 
purchased from Intercell Technologies (Hopewell, N.J.). 
Heart transplantation was done 12 to 21 days later. 
Flow cytometry. Cells for flow cytometric study were 
obtained from spleen and lymph nodes of the animal to be 
tested and were prepared in the same manner already 
described. Two-color analysis was done. Simultaneous 
staining was done with phycoerythrin-labeled anti-CD3 
antibody for the identification of T cells and fluorescein 
isothiocyanate-labeled antibodies for the identification of 
the different V beta receptors. Cells were counted with 
use of a Becton Dickinson fluorescence-activated c ll 
sorter. The T-cell receptor regions evaluated were V beta 
2, 3, 5.1/5.2, 6, 7, 8.1/8.2, 9, 10, 11, 12, 13, 14, and 17a. All 
antibodies were purchased from Pharmingen (San Diego, 
Calif.). The percentages of cells that stained positive for 
both CD3 and each V beta region were calculated. Cells 
from naive, sensitized, and tolerant animals were studied. 
Sensitized animals underwent cardiac grafting without 
pretreatment. Analysis was done on about day 25 when 
the rejection process was established. Cells from tolerant 
animals were studied after 100 days with a beating heart 
graft. 
Results 
Results of intrathymic manipulation are shown in 
Table I. The mean survival time of the heart grafts 
in the untreated group was 20.4 days. ALS alone did 
not prolong graft survival significantly. Mice treated 
with ALS and intrathymic splenocytes had indefinite 
heart graft survival (>100 days). Third-party 
BALB/c grafts placed in treated animals were re- 
jected normally. 
Flow cytometry results are shown in Table II. Five 
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Table I. Effect of intrathymic manipulation on graft 
survival 
MST +_ SD LST  
Groups n (days) (days) 
Naive 9 20.4 _+ 11.0 49 
ALS 5 25.8 _+ 9.3 38 
ALS and intrathymic 12 >100.0 + 0.0" >100 
injection 
Third party 4 11.8 _+ 1.3 13 
MST, Mean survival time; SD, standard eviation; LST, longest survival 
time. 
*p < 0.0001. 
V beta receptor egions showed significant changes 
in percent expression in sensitized animals and in 
animals made tolerant by intrathymic pretreatment. 
Of note, the percentage ofT cells bearing the V beta 
7 region was increased from 3.77% to 8.3% in 
sensitized mice. Expression of V beta 7 was virtually 
eliminated in tolerant mice. 
Discussion 
This study demonstrates the feasibility of using 
our mouse model of organ transplantation for the 
molecular study of important events in transplant 
rejection and acquired tolerance. We are convinced 
that understanding at the level of the molecules is 
important in advancing our understanding of these 
important processes and in advancing therapy for 
organ transplant recipients. The solution of the 
crystal structure of the MHC molecule 1°' 11 provided 
opportunities for explosive growth in the under- 
standing of fundamental immune processes. Similar 
explosive growth is possible in transplantation science 
if we can develop molecular immunologic bases for 
understanding graft rejection and its control. 
Our work supports our hypothesis that a molec- 
ularly discrete transplantation a tigen elicits a T-cell 
immune response that is marked by limited hetero- 
geneity of T-cell receptor expression. We have ob- 
served apparent critical importance of the T-cell 
receptor/3 chain variable segment V beta 7 in the 
rejection response of a C57BL/6 mouse to a bin1 
heart graft. Limited heterogeneity of receptor ex- 
pression has been observed in other immune systems 
in which the response is to an antigen of discrete 
molecular structure. Similar observations have been 
made in models of allergic encephalitis ~2' 13 and arthri- 
tis 14 and in the physiologic immune response to the 
Mls antigen. ~5 This makes intuitive sense because the 
purpose of T-cell receptor fine specificity is the distinc- 
tion of subtle molecular differences. 
Table II. Percentage V beta region T-cell receptor 
expression 
V beta n Naive Sensitized Tolerant 
2 5 6.90 -+ 0.34 6.80 -+ 1.80 7.19 + 1.71 
3 5 3.49 -+ 0.76 3.43 -+ 0.31 3.37 -+ 0.43 
5.1 5 1.24 + 0.60 3.87 -+ 1.05" 7.70 -+ 0.59"t 
6 5 7.59 -+ 1.33 10.13 -+ 2.89 12.10 _+ 1.74" 
7 5 3.77 -+ 2.00 8.29 -+ 0.71" 0.43 +-- 0.14*t 
8.1, 8.2 5 18.79-+ 1.21 17.46 +-- 1.35 20.08-+ 0.52t 
9 5 3.25 --+ 0.66 4.26 -+ 1.42 5.77 -+ 2.28 
10 5 5.12 -+ 0.79 5.09 -+ 0.54 8.52 -+ 3.14 
11 5 5.41 -+ 0.15 4.68 -+ 0.21 5.56 -+ 0.70 
12 5 5.77 -+ 0.53 7.56 -+ 0.50* 10.47 -+ 2.18"]" 
13 5 3.30 -+ 0.62 1.08 -+ 0.20* 1.68 +- 0.45* 
14 5 5.43 -+ 1.21 6.17 -+ 0.41 5.95 -+ 0.79 
17a 5 3.15 _+ 1.12 5.76 _+ 0.41' 4.49 _+ 0.62 
*p = 0.005 (naive versus ensitized/tolerant). 
tp = 0.005 (sensitized versus tolerant). 
Our data also begin to provide insight into the 
mechanism by which pretransplant intrathymic ma- 
nipulations produce acquired tolerance to alloge- 
neic tissues. Since the initial description of the 
efficacy of intrathymic pretreatment with alloanti- 
gen, 6 investigators have speculated that this treat- 
ment strategy produces acquired tolerance by alter- 
ing the immune-cell repertoire. In an analogy to 
normal immune ontogeny, 16-18 placement of alloge- 
neic cells in the thymus is thought to lead to the 
deletion of T lymphocytes that ordinarily respond to 
these alloantigens. The theory is that the single dose 
of antilymphocyte s rum depletes the body of ma- 
ture lymphocytes including those that would re- 
spond to an allograft. When the lymphocyte popu- 
lation is reconstituted with new T cells that mature 
in the thymus after introduction of alloantigen the 
altered thymic milieu leads to deletion of alloreac- 
tive cells. Our data showing elimination of V beta 7 
receptor expression in tolerant animals is evidence 
in favor of a deletion mechanism as an important 
component of tolerance in this system. 
We have not in this model investigated other 
potential mechanisms of tolerance induction includ- 
ing the development of immune anergy or a distinct 
population of suppressor cells. In separate xperi- 
ments in a rat model we have shown a transferable 
cell population that leads to prolonged allograft 
survival although permanent tolerance has not been 
achieved (unpublished ata). It is possible that 
intrathymic pretreatment produces a variety of 
mechanisms whereby permanent allograft survival is 
achieved. Understanding of this phenomenon re- 
quires future study. 
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Other investigation is also required to develop a 
complete understanding of our present observa- 
tions. It would be desirable to analyze receptor 
expression on the lymphocytes that actually invade 
heart grafts. We hypothesize that the V beta 7 
receptor chain would predominate on lymphocytes 
harvested from rejected grafts. Other planned inves- 
tigations include studying the effects of monoclonal 
antibodies to specific receptor chains in the in vivo 
transplant model and in vitro assays such as the 
mixed lymphocyte reaction. We plan to extend our 
study to other bm mutations, which offer the oppor- 
tunity to study the differential response to other 
alterations in the molecular configuration of H-2K b. 
For instance, bin23 has substitutions in a different 
portion of the opposite alpha helix of the class I 
molecule and might be expected to elicit a response 
from a different population of T cells expressing a
different receptor chain. 
Finally, we need to modify our pretreatment 
protocols uch that this Strategy might be applicable 
to clinical transplant situations. One logical set of 
experiments 'would be to compress the pretreatment 
interval to several hours before transplantation. For 
instance, anti lymphocyte serum could be given 3 to 
6 hours before intrathymic inoculation with alloge- 
neic cells and performance of the tissue allograft. It 
is easy to envision how this protocol might be 
applied clinicaUy and therefore it is important to 
determine wlhether such treatment produces signif- 
icant prolongation of graft survival. If so, appropri- 
ate clinical trials might be indicated. 
We are committed to the concept hat the control 
of allograft rejection in a nontoxic and specific 
fashion requires a molecular immunologic under- 
standing of the important events in rejection. We 
believe that our preliminary work establishes the 
potential efficacy of our mouse model for studying 
these processes at the molecular level. Furthermore, 
our data suggest hat the intrathymic pretreatment 
strategy can he studied productively at a fundamen- 
tal level and may produce insights that will be useful 
in clinical organ transplantation. 
REFERENCES 
1. DiSesa VJ. Molecular immunology ofthe allograft rejection: 
insight from MHC mutants and crystal structure. J Heart 
Lung Transplant 1991;10:111-6. 
2. Nathenson SG, Geliebter J, Pfaffenbach GM, et al. Murine 
major histocompatibility complex class I mutants: molecular 
analysis and structure function implications. Annu Rev Im- 
munol 1986;4:471-502. 
3. Kline GM, Shen Z, Mohiuddin M, et al. Successful experi- 
mental heart transplantation without immunosuppressive 
drugs. J Heart Lung Transplant 1993;12:388-93. 
4. Shen Z, Kline GM, Mohiuddin M, DiSesa VJ. Histocompat- 
ibility differences and cardiac transplant tolerance produced 
by intrathymic pretreatment. J Thorac Cardiovasc Surg 1994; 
107:1472-5. 
5. Shen Z, Mohiuddin M, DiSesa VJ. Durability of donor- 
specific and organ-specific heart ransplant tolerance induced 
by intrathymic pretreatment with allogeneic spleen cells. Surg 
Forum 1994;45:237-9. 
6. Posselt AM, Campos L, Mayo GL, et al. Selective modula- 
tion of T-cell immunity by intrathymic cellular transplanta- 
tion. Transplant Rev 1993;7:200-13. 
7. Odorico JS, Posselt AM, Naji A, et al. Promotion of rat 
cardiac allograft survival by intrathymic noculation of donor 
splenocytes. Transplantation 1993;55:1104-7. 
8. Goss JA, Nakafusa Y, Yu S, Flye MW. Intrathymic njection 
of donor alloantigens induces pecific tolerance to cardiac 
allografts. Transplantation 1993;56:166-73. 
9. Fulmer RI, Cramer AT, Libelt RA, et al. Transplantation f
the cardiac tissue in the mouse ar. Am J Anat 1963;118:273. 
10. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, 
Strominger JL, Wiley DC. Structure of the human class 1 
histocompatibility antigen, HLA-A2. Nature 1987;329:506-12. 
11. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, 
Strominger JL, Wiley DC. The foreign antigen binding site 
and T cell recognition regions of class I histocompatibility 
antigens. Nature 1987;329:512-8. 
12. Kuchroo VK, Sobel RA, Laning JC, et al. Experimental 
allergic encephalomyelitis mediated by cloned T cells specific 
for a synthetic peptide of myelin proteolipid protein: fine 
specificity and T ceil receptor V beta usage. J Immnnol 
1992;148:3776-82. 
13. Kotzin BL, Karuturi S, Chou YK, et al. Preferential T-cell 
receptor beta chain variable gene use in myelin basic protein- 
reactive T-cell clones from patients with multiple sclerosis. 
Proc Natl Acad Sci U S A 1991;88:9161-5. 
14. Haqqi TM, Anderson GD, Banerjee S, et al. Restricted 
heterogeneity n T-cell antigen receptor V beta gene usage in 
the lymph nodes and arthritic joints of mice. Proc Natl Acad 
Sci U S A 1992;89:1253-5. 
15. MacDonald HR, Schneider R, Lees RK, et al. T-cell receptor 
V beta use predicts reactivity and tolerance to Mlsa-encoded 
antigens. Nature 1988;332:40-5. 
16. Kronenberg M. Self-tolerance and autoimmunity. Cell 1991; 
65:537-42. 
17. Blackman M, Kappler J, Marrack P. The role of the T cell 
receptor in positive and negative selection of developing T 
cells. Science 1990;248:1335-41. 
18. Schwartz RH. Acquisition of immunologic self-tolerance. 
Cell 1989;57:1073-81. 
